Literature DB >> 2702675

Treatment of glioma with intratumoral instillation of autologous lymphocytes.

S N Bhagwati1.   

Abstract

Autologous lymphocytes were instilled into the tumor in a girl 15 years of age who had presented with a recurrent left frontoparietal astrocytoma 1.5 years after surgery, radiation, and chemotherapy. She had remissions for 5 weeks, 5 months, and 20 months after the first, second, and third instillations, respectively. The usefulness of intratumoral instillation of autologous lymphocytes [or preferably lymphokine activated killer (LAK) cells with interleukin-2 is demonstrated in such recurrent astrocytomas.

Entities:  

Mesh:

Year:  1989        PMID: 2702675     DOI: 10.1007/BF00706746

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  16 in total

Review 1.  Cell-mediated immunity to tumor cells.

Authors:  R B Herberman
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

2.  Cell-mediated immunity and blocking factors in patients with tumours of the central nervous system.

Authors:  S Kumar; G Taylor; J K Steward; M A Waghe; P Morris-Jones
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

Review 3.  Immunological aspects of intrinsic glial tumors.

Authors:  M L Apuzzo; M S Mitchell
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

4.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

5.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

6.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

7.  Specific cellular immune responses in patients with malignant gliomas.

Authors:  K M Sheikh; M L Apuzzo; M H Weiss
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

8.  Mechanisms by which human gliomas may escape cellular immune attack.

Authors:  M K Gately; M Glaser; R M McCarron; S J Dick; M D Dick; R W Mettetal; P L Kornblith
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  4 in total

1.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Authors:  S K Sankhla; J S Nadkarni; S N Bhagwati
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Sanat Bhagwati (1928-2013): a tribute.

Authors:  Chandrashekhar Eknath Deopujari
Journal:  Childs Nerv Syst       Date:  2015-03-05       Impact factor: 1.475

3.  Cytotoxicity of rat marrow stromal cells against malignant glioma cells.

Authors:  Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Do Sung Yoo; Pil Woo Huh; Kyung Souk Cho; Dal Soo Kim; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2005-06-03       Impact factor: 1.475

4.  Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Authors:  Seok-Gu Kang; Chung Hun Ryu; Sin Soo Jeun; Chun Kun Park; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2004-02-13       Impact factor: 1.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.